Literature DB >> 12814249

Proliferative activity of microvascular cells in glioblastomas does not correlate with time to recurrence.

Michael A Kern1, Klaus D Feisel, Michael Friese, Ralf-Ingo Ernestus, Roland Schröder.   

Abstract

The time to recurrence operation (TR) is a good growth parameter, in particular for glioblastomas. Recently, we have shown that Ki-67 labeling index (LI) of tumor cells has a high inverse correlation with this time interval. In the current study, the LI of microvascular cells (MVC) was examined in the same glioblastoma cases. The LI of MVC of primary and recurrent tumors had no relationship and did not show any correlation to TR. The growth fraction of MVC was significantly lower than that of tumor cells. The MVC in glioblastomas seems to have chaotical proliferation properties without any link to the tumor growth potential. This observation may have implications for anti-angiogenic therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12814249     DOI: 10.1023/a:1023795417525

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  20 in total

1.  Quantitative analysis of microvascular changes in diffuse astrocytic neoplasms with increasing grade of malignancy.

Authors:  P Wesseling; J A van der Laak; M Link; H L Teepen; D J Ruiter
Journal:  Hum Pathol       Date:  1998-04       Impact factor: 3.466

Review 2.  Tumor angiogenesis: therapeutic implications.

Authors:  J Folkman
Journal:  N Engl J Med       Date:  1971-11-18       Impact factor: 91.245

3.  Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2.

Authors:  P Kunkel; U Ulbricht; P Bohlen; M A Brockmann; R Fillbrandt; D Stavrou; M Westphal; K Lamszus
Journal:  Cancer Res       Date:  2001-09-15       Impact factor: 12.701

4.  Early and extensive contribution of pericytes/vascular smooth muscle cells to microvascular proliferation in glioblastoma multiforme: an immuno-light and immuno-electron microscopic study.

Authors:  P Wesseling; R O Schlingemann; F J Rietveld; M Link; P C Burger; D J Ruiter
Journal:  J Neuropathol Exp Neurol       Date:  1995-05       Impact factor: 3.685

5.  The labelling of proliferating cells by Ki67 and MIB-1 antibodies depends on the binding of a nuclear protein to the DNA.

Authors:  F Lopez; F Belloc; F Lacombe; P Dumain; J Reiffers; P Bernard; M R Boisseau
Journal:  Exp Cell Res       Date:  1994-02       Impact factor: 3.905

6.  Proliferative potential of vascular components in human glioblastoma multiforme.

Authors:  T Nagashima; T Hoshino; K G Cho
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

7.  Vascular smooth muscle hyperplasia underlies the formation of glomeruloid vascular structures of glioblastoma multiforme.

Authors:  S F Haddad; S A Moore; R L Schelper; J A Goeken
Journal:  J Neuropathol Exp Neurol       Date:  1992-09       Impact factor: 3.685

8.  Immunohistochemical detection of factor VIII/von Willebrand factor in hyperplastic endothelial cells in glioblastoma multiforme and mixed glioma-sarcoma.

Authors:  R D McComb; T R Jones; S V Pizzo; D D Bigner
Journal:  J Neuropathol Exp Neurol       Date:  1982-09       Impact factor: 3.685

9.  Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma.

Authors:  A S Chan; S Y Leung; M P Wong; S T Yuen; N Cheung; Y W Fan; L P Chung
Journal:  Am J Surg Pathol       Date:  1998-07       Impact factor: 6.394

10.  Correlation between the bromodeoxyuridine labeling index and the MIB-1 and Ki-67 proliferating cell indices in cerebral gliomas.

Authors:  K Onda; R L Davis; M Shibuya; C B Wilson; T Hoshino
Journal:  Cancer       Date:  1994-10-01       Impact factor: 6.860

View more
  1 in total

1.  Role of MIB1 in predicting survival in patients with glioblastomas.

Authors:  Shaye I Moskowitz; Tao Jin; Richard A Prayson
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.